Cellectis Q2 Adj EPS $(0.15) Beats $(0.45) Estimate, Sales $2.00M Miss $4.48M Estimate
Portfolio Pulse from vinayak@benzinga.com
Cellectis reported Q2 adjusted EPS of $(0.15), beating the estimate of $(0.45) by 66.67%. However, the company's sales of $2.00M missed the estimate of $4.48M by 55.31%. This represents a 58.33% increase in losses and a 27.59% decrease in sales compared to the same period last year.
August 04, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cellectis' Q2 earnings beat estimates but sales missed, indicating mixed performance.
Cellectis' Q2 earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These mixed results could lead to uncertainty and volatility in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100